Results 181 to 190 of about 25,773 (228)
Some of the next articles are maybe not open access.
Journal of Gastroenterology and Hepatology (Australia), 2010
AbstractBackground and Aim: To evaluate the usefulness of quantitative hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) for predicting HBeAg seroconversion in chronic hepatitis B patients treated with conventional interferon (IFN) alfa‐2b or PegIFN alfa‐2b.Methods: Fifty‐eight patients were enrolled; 29 for the training group and
Rui-Feng Yang
exaly +3 more sources
AbstractBackground and Aim: To evaluate the usefulness of quantitative hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) for predicting HBeAg seroconversion in chronic hepatitis B patients treated with conventional interferon (IFN) alfa‐2b or PegIFN alfa‐2b.Methods: Fifty‐eight patients were enrolled; 29 for the training group and
Rui-Feng Yang
exaly +3 more sources
Journal of Viral Hepatitis, 2010
Summary. Loss of hepatitis ‘e’ antigen (HBeAg) in patients with HBeAg‐positive chronic hepatitis B is associated with improved long‐term clinical outcome and is defined as a goal of antiviral treatment by clinical practice guidelines. Recent studies suggest that baseline levels and on‐treatment monitoring of HBeAg levels may identify patients most ...
Wursthorn, Karsten +5 more
openaire +2 more sources
Summary. Loss of hepatitis ‘e’ antigen (HBeAg) in patients with HBeAg‐positive chronic hepatitis B is associated with improved long‐term clinical outcome and is defined as a goal of antiviral treatment by clinical practice guidelines. Recent studies suggest that baseline levels and on‐treatment monitoring of HBeAg levels may identify patients most ...
Wursthorn, Karsten +5 more
openaire +2 more sources
Journal of Viral Hepatitis, 2011
Summary. There are few reports on hepatitis B e antigen (HBeAg) titres during nucleos(t)ide analogues treatment. We investigated the changes in HBeAg levels in patients treated with entecavir and the usefulness of HBeAg quantification for predicting antiviral response.
J H, Kwon +6 more
openaire +2 more sources
Summary. There are few reports on hepatitis B e antigen (HBeAg) titres during nucleos(t)ide analogues treatment. We investigated the changes in HBeAg levels in patients treated with entecavir and the usefulness of HBeAg quantification for predicting antiviral response.
J H, Kwon +6 more
openaire +2 more sources
HBeAg in Viral Hepatitis Type B
Digestion, 200958 patients with acute hepatitis type B, including 13 with fulminant hepatitis, were tested on presentation for HBeAg. Positive results were obtained in 24%. The frequency was highest in those with fulminant hepatitis (46% positive), and this was probably related to the earlier presentation of patients with this condition. Patients with acute hepatitis
I L, Woolf +4 more
openaire +2 more sources
Characterization of hbeag by physicochemical and immunochemical methods
Journal of Medical Virology, 1980AbstractHBeAg, which is a hepatitis B‐associated antigen, was purified and characterized. The end product from ion exchange, gel filtration and immunoadsorbent columns consisted mainly of immunoglobulin G (IgG) molecules, identified by immunoelectrophoresis and polyacrylamide gel electrophoresis.
D, Katz, J L, Melnick, F B, Hollinger
openaire +2 more sources
Hepatology International, 2014
It remains unclear whether chronic hepatitis B patients who undergo interferon (IFN)-induced hepatitis B e antigen (HBeAg) seroconversion have a higher risk of hepatitis B virus (HBV) reactivation and HBeAg seroreversion than those with spontaneous HBeAg seroconversion.A total of 80 and 251 non-cirrhotic patients with interferon-induced and spontaneous
Chien-Hung, Chen +5 more
openaire +2 more sources
It remains unclear whether chronic hepatitis B patients who undergo interferon (IFN)-induced hepatitis B e antigen (HBeAg) seroconversion have a higher risk of hepatitis B virus (HBV) reactivation and HBeAg seroreversion than those with spontaneous HBeAg seroconversion.A total of 80 and 251 non-cirrhotic patients with interferon-induced and spontaneous
Chien-Hung, Chen +5 more
openaire +2 more sources
Quantitative HBeAg is a strong predictor of HBeAg loss among patients receiving pegylated interferon
Antiviral ResearchHBeAg loss is an important endpoint for antiviral therapy in chronic hepatitis B (CHB), however there are no reliable biomarkers to identify patients who will respond to the addition of pegylated interferon to nucleos(t)ide analogue (NA) therapy.To evaluate the use of serum biomarkers to predict HBeAg loss.HBeAg positive CHB participants on NAs who ...
Daniel Q. Huang +23 more
openaire +2 more sources
Hepatology
Background and Aims: The outcomes and benefits of antiviral therapy in patients with indeterminate phase HBeAg-negative chronic hepatitis B are not well described in treatment guidelines. We examined HCC risk among these patients. Approach and Results:
Vicki Wing-Ki Hui +8 more
openaire +2 more sources
Background and Aims: The outcomes and benefits of antiviral therapy in patients with indeterminate phase HBeAg-negative chronic hepatitis B are not well described in treatment guidelines. We examined HCC risk among these patients. Approach and Results:
Vicki Wing-Ki Hui +8 more
openaire +2 more sources
Liver International, 2011
Abstract Background and aims: This cohort study investigated the long‐term effect of maternal hepatitis B virus (HBV) sero‐status on the spontaneous HBeAg seroconversion in offspring with chronic HBV infection. Methods: A total of 185 HBeAg‐positive chronic HBV‐infected children, with maternal HBV seromarkers checked, were ...
Jia-Feng Wu, Wan-Hsin Wen, Yen-Hsuan Ni
exaly +3 more sources
Abstract Background and aims: This cohort study investigated the long‐term effect of maternal hepatitis B virus (HBV) sero‐status on the spontaneous HBeAg seroconversion in offspring with chronic HBV infection. Methods: A total of 185 HBeAg‐positive chronic HBV‐infected children, with maternal HBV seromarkers checked, were ...
Jia-Feng Wu, Wan-Hsin Wen, Yen-Hsuan Ni
exaly +3 more sources
Journal of Viral Hepatitis, 2018
SummaryHBeAg seroconversion marks an important spontaneous change and treatment end‐point for HBeAg‐positive patients and is a pre‐requisite for HBsAg loss or functional cure. In this retrospective analysis, we aimed to identify predictors of seroconversion using serum quantitative HBsAg and HBcrAg, in HBeAg‐positive patients treated with nucleos(t)ide
B. Wang +5 more
openaire +3 more sources
SummaryHBeAg seroconversion marks an important spontaneous change and treatment end‐point for HBeAg‐positive patients and is a pre‐requisite for HBsAg loss or functional cure. In this retrospective analysis, we aimed to identify predictors of seroconversion using serum quantitative HBsAg and HBcrAg, in HBeAg‐positive patients treated with nucleos(t)ide
B. Wang +5 more
openaire +3 more sources

